Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumours

6 Sept 2011

Abstract excerpt

BACKGROUND: Ovarian cancer is a leading cause of gynaecological cancer-related morbidity and mortality. There has been increasing interest in the potential utility of anti-human epidermal growth factor receptor 2 (anti-HER2) agents in the treatment of this disease, with the attendant need to identify suitable predictive biomarkers of response to treatment. AIMS/METHODS: The authors studied the prevalence of HER2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Biosensing Techniques and Applications
Share to HER2/EGFR in Cancer Research
Share to Ovarian cancer diagnosis and treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 21896578
DOI: 10.1136/jclinpath-2011-200082

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dual-colour HER2/chromosome 17 chromogenic in situ hybridisation enables accurate assessment of HER2 genomic status in ovarian tumoursPMID 21896578Read ↗

Dual-colour HER2/Chromosome 17 chromogenic in situ hybridisation assay enables accurate assessment of HER2 genomic status in gastric cancer and has potential utility in HER2 testing of biopsy samplesSemantic proximity Read ↗

Determination of <i>HER2</i> amplification in primary breast cancer using dual‐colour chromogenic <i>in situ</i> hybridization is comparable to fluorescence <i>in situ</i> hybridization: a European multicentre study involving 168 specimensSemantic proximity Read ↗

Evaluation of HER2 gene amplification in invasive breast cancer using a dual-color chromogenic in situ hybridization (dual CISH)Semantic proximity Read ↗

Interlaboratory Comparison of<b><i>HER-2</i></b>Oncogene Amplification as Detected by Chromogenic and Fluorescence<b><i>in situ</i></b>HybridizationSemantic proximity Read ↗

Chromogenic in situ hybridization (CISH) to detect HER2 gene amplification in breast and gastric cancer: Comparison with immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH)Semantic proximity Read ↗

Chromogenic in situ hybridisation for the assessment of HER2 status in breast cancer: an international validation ring studySemantic proximity Read ↗

Characteristics of HER2 Gene Amplification by Fluorescence In Situ Hybridization in Endometrial Serous Carcinoma: Implications for Clinical HER2 Testing and InterpretationSemantic proximity Read ↗

HER2 Positivity in Breast Carcinoma: A Comparison of Chromogenic In Situ Hybridization With Fluorescence In Situ Hybridization in Tissue Microarrays, With Targeted Evaluation of Intratumoral Heterogeneity by In Situ HybridizationSemantic proximity Read ↗

A UK NEQAS ISH Multicenter Ring Study Using the Ventana <i>HER2</i> Dual-Color ISH AssaySemantic proximity Read ↗

Development of automated brightfield double In Situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence In Situ hybridization (FISH)Semantic proximity Read ↗

Chromogenic <i>in situ</i> hybridization for Her‐2/neu‐oncogene in breast cancer: comparison of a new dual‐colour chromogenic <i>in situ</i> hybridization with immunohistochemistry and fluorescence <i>in situ</i> hybridizationSemantic proximity Read ↗

Comparison of different commercial kits for HER2 testing in breast cancer: looking for the accurate cutoff for amplificationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.